ctDNA | pharmaphorum

Skip to main content

Wednesday 16 September 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

ctDNA

Oncology

Solid tumour spreading

Sponsored

Establishing ctDNA as a validated primary surrogate endpoint

Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.

Oncology

migrating breast cancer cell

Liquid biopsy and the future of tumour-agnostic treatments

Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.

Oncology

oncological practices today, with ESMO branding

5 clinical advances and related implications from ESMO 2025

5 particularly insightful takeaways from this year’s ESMO Congress that merit deeper reflection on where cancer care can go.

Oncology

Sven Schaffer and Nicole Raleigh interview at ESMO

ESMO 2024 - Sven Schaffer

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.

Editor's Picks

FDA overrides adcomm and approves AZ's oral SERD

Novartis falls sharply on another major R&D setback

Could UK clinical trial revamp unlock closer ties with Canada?

FDA makes acting CDER, CBER chiefs permanent

UK review recommends 'L plates' for new healthcare AIs

News

Wales takes UK lead on needle-free anaphylaxis prevention

Wales takes UK lead on needle-free anaphylaxis prevention

Wales has recommended ALK's EURneffy nasal spray as a needle-free option for emergency treatment of severe allergic reactions, including anaphylaxis.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company